• REEM HASABALLAH ALHASANI Department of Biology, Faculty of Applied Science, Umm Al-Qura University, Makkah, Saudi Arabia
  • NORAH A. ALTHOBAITI Biology Department, College of Science and Humanities-Al Quwaiiyah, Shaqra University, Al Quwaiiyah 19257, Saudi Arabia
  • SALMA SALEH ALRDAHE Department of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia



Prostate cancer, Prostatitis, Magnetic resonance, Hyperplasia, Malignant prostate


Prostate cancer (PC) is the most common malignancy among men and is the fifth leading cause of cancer-related death in men worldwide. The present study aims to systematically review the ability of magnetic resonance spectroscopy (MRS) to differentiate between benign and malignant prostate lesions. According to the 06-PRISMA guideline, we searched in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar without time limitation for publications related to the role of magnetic resonance spectroscopy for prostate cancer diagnosis. The searched words and terms were: “prostate cancer”, “prostatitis”, “magnetic resonance spectroscopy”, “benign prostate hyperplasia”, “malignant prostate hyperplasia”, “comparison”. Totally 1927 papers were identified by database searching. Out of these papers, 261 papers were discarded because of duplication. Of the remaining 1666 papers, 1604 papers were discarded because of the inadequate information and the ones in which the abstract was submitted in congresses as preceding papers, conferences, and editorials without full text. Out of the remaining 62 papers which were studied for eligibility, 52 papers were removed for a number of reasons including inconsistency between methods with results, incorrect interpretation of the results, poor methodology, etc. Finally, 10 papers were included in this present study. In general, based on the results of the review of articles, MRS has optimal sensitivity, specificity and accuracy in diagnosing prostate cancer and differentiating it from benign prostate hyperplasia in comparison with other diagnostic and pathological methods. Due to the small number of studies related to the sensitivity and specificity of MRS, further checking was not possible to confirm these results. Therefore, further studies in this regard are recommended.


Download data is not yet available.


Morgan SC, Holmes OE, Craig J, Grimes S, Malone S. Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(4):1041-7. doi: 10.1038/s41391-021-00339-y.

Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, Benard V, Henley SJ, Anderson RN, Fedewa S, Sherman RL, Kohler BA, Dearmon BJ, Lake AJ, Ma J, Richardson LC, Jemal A, Penberthy L. Annual report to the nation on the status of cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801-14. doi: 10.1002/cncr.31549, PMID 29786851.

Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314(19):2054-61. doi: 10.1001/jama.2015.14905, PMID 26575061.

Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807-23. doi: 10.1177/1557988318798279, PMID 30203706.

Satapathy S, Sood A, Das CK, Mittal BR. Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24(3):880-90. doi: 10.1038/s41391-021-00349-w, PMID 33746213.

Denny DC, SSY, RV, Fardan M. Iype Ds, K Am. Cardiovascular risk associated with androgen deprivation therapy in advanced prostate cancer. Asian J Pharm Clin Res. 2021;14(8):6-9.

Ferlay J, EM LF, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco,fr:iarc/today [Last accessed on 02 Feb 2019].

Cancer Stat Facts. Prostate cancer [internet]; 2018. Seer. Available from: html/prost.html. [Last accessed on 22 Jan 2022]

US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M, Epling JW, Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Siu AL, Tseng CW. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-13. doi: 10.1001/jama.2018.3710, PMID 29801017.

Begum SA, Rani SJ, Banu A, Pavani A, Yeruva V. Statistics of cancer, 2020 in Indian states: a review on the report from national cancer registry programme. Asian J Pharm Clin Res. 2021;14(6):36-42. doi: 10.22159/ajpcr.2021.v14i6.41616.

Hosain GM, Sanderson M, Du XL, Chan W, Strom SS. Racial/ethnic differences in predictors of PSA screening in a tri-ethnic population. Cent Eur J Public Health. 2011;19(1):30-4. doi: 10.21101/cejph.a3622, PMID 21526653.

Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15(1):45-55. doi: 10.1038/pcan.2011.35, PMID 21844889.

Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, Heber D, Kobayashi N. Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol. 2010;183(1):345-50. doi: 10.1016/j.juro.2009.08.104, PMID 19914662.

Venkateswaran V, Klotz LH. Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol. 2010;7(8):442-53. doi: 10.1038/nrurol.2010.102, PMID 20647991.

Stram DO, Hankin JH, Wilkens LR, Park S, Henderson BE, Nomura AM, Pike MC, Kolonel LN. Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study* (United States). Cancer Causes Control. 2006;17(9):1193-207. doi: 10.1007/s10552-006-0064-0, PMID 17006725.

Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571-8. doi: 10.1002/ijc.22788, PMID 17450530.

Bass EJ, Pantovic A, Connor M, Gabe R, Padhani AR, Rockall A, Sokhi H, Tam H, Winkler M, Ahmed HU. A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. Prostate Cancer Prostatic Dis. 2021;24(3):596-611. doi: 10.1038/s41391-020-00298-w, PMID 33219368.

Sesso HD, Paffenbarger RS Jr, Lee IM. Alcohol consumption and risk of prostate cancer: the harvard alumni health study. Int J Epidemiol. 2001 Aug;30(4):749-55. doi: 10.1093/ije/30.4.749, PMID 11511598.

Taylor ML, Mainous AG, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med. 2005 Jul–Aug;37(7):506-12. PMID 15988645.

Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800-9. doi: 10.1016/j.eururo.2012.11.013, PMID 23219374.

Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019;6(2):129-36. doi: 10.1016/j.ajur.2018.11.007, PMID 31061798.

Alaryani FS, Turki Alrdahe SS. A review of treatment, risk factors, and incidence of colorectal cancer. Int J Appl Pharm. 2022;14(1):1-6. doi: 10.22159/ijap.2022v14i1.42820.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P. Pronostic biomarkers used for localized prostate cancer management: asystematic review. Eur Urol Focus. 2017;7:30065e72.

Jones D, Friend Ch, Dreher A, Allgar V, Macleod U. The diagnostic test accuracy of rectal examination for prostate cancer diagnosis in symptomatic patients: a systematic review. BMC Fam Pract. 2018;19(1):79. doi: 10.1186/s12875-018-0765-y, PMID 29859531.

Tyson MD, Arora SS, Scarpato KR, Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol 2016;34:326e32.

Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015;68(3):438-50. doi: 10.1016/j.eururo.2014.11.037, PMID 25480312.

Martin H, Maurer J, Heverhagen T. Diffusion-weighted imaging of the prostate-principles, application, and advances. Transl Androl Urol. 2017 Jun;6(3):490-8.

Barentsz J, de Rooij M, Villeirs G, Weinreb J. Prostate imaging-reporting and data system version 2 and the implementation of high-quality prostate magnetic resonance imaging. Eur Urol Version 2. 2017;72(2):189-91. doi: 10.1016/ j.eururo.2017.02.030, PMID 28262414.

Thormer G, Otto J, Horn LC, Garnov N, Do M, Franz T, Stolzenburg JU, Moche M, Kahn T, Busse H. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T. Acta Radiol. 2015;56(1):121-8. doi: 10.1177/0284185113520311, PMID 24504488.

Cornel EB, Smits GAHJ, Oosterhof GON, Karthaus HFM, Debruyne FMJ, Schalken JA, Heerschap A. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1 H and 31 P magnetic resonance spectroscopy. J Urol. 1993;150(6):2019-24. doi: 10.1016/S0022-5347(17)35957-8.

Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45(3):459-66. doi: 10.1016/S0090-4295(99)80016-8, PMID 7533458.

Kim JK, Kim DY, Lee YH, Sung NK, Chung DS, Kim OD, Kim KB. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external-body surface coil. Magn Reson Imaging. 1998;16(10):1281-8. doi: 10.1016/s0730-725x(98)00110-6, PMID 9858286.

Garcia Segura JM, Sanchez Chapado M, Ibarburen C, Viano J, Angulo JC, Gonzalez J, Rodriguez Vallejo JM. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magn Reson Imaging. 1999;17(5):755-65. doi: 10.1016/s0730-725x(99)00006-5, PMID 10372529.

Yue K, Marumoto A, Binesh N, Thomas MA. 2D JPRESS of human prostates using an endorectal receiver coil. Magn Reson Med. 2002;47(6):1059-64. doi: 10.1002/mrm.10160, PMID 12111951.

Giskeødegard GF, Hansen AF, Bertilsson H, Gonzalez SV, Kristiansen KA, Bruheim P, Mjøs SA, Angelsen A, Bathen TF, Tessem MB. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. Br J Cancer. 2015;113(12):1712-9. doi: 10.1038/bjc.2015.411, PMID 26633561.

Meier Schroers M, Kukuk G, Wolter K, Decker G, Fischer S, Marx C, Traeber F, Sprinkart AM, Block W, Schild HH, Willinek W. Differentiation of prostatitis and prostate cancer using the prostate imaging-reporting and data system (PI-RADS). Eur J Radiol. 2016;85(7):1304-11. doi: 10.1016/j.ejrad.2016.04.014, PMID 27235878.

Zhang TH, Hu CH, Chen JX, Xu ZD, Shen JK. Differentiation diagnosis of hypo-intense t2 area in unilateral peripheral zone of prostate using magnetic resonance spectroscopy (MRS): prostate carcinoma versus prostatitis. Med Sci Monit. 2017;23:3837-43. doi: 10.12659/MSM.903123, PMID 28790299.

Zhang XQ, Yu XR, Du ZL, Miao XF, Lu J, Zhou Q. Three-dimensional proton magnetic resonance spectroscopy and diffusion-weighted imaging in the differentiation of incidental prostate carcinoma from benign prostate hyperplasia. Oncol Lett. 2018;15(5):6541-6. doi: 10.3892/ol.2018.8131, PMID 29616121.

Mazaheri Y, Shukla Dave A, Goldman DA, Moskowitz CS, Takeda T, Reuter VE, Akin O, Hricak H. Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla. Magn Reson Imaging. 2019;55:93-102. doi: 10.1016/j.mri.2018.08.025. PMID 30176373.

Barentsz J, de Rooij M, Villeirs G, Weinreb J. Prostate imaging-reporting and data system version 2 and the implementation of high-quality prostate magnetic resonance imaging. Eur Urol Version 2. 2017;72(2):189-91. doi: 10.1016/j.eururo.2017.02.030, PMID 28262414.

Kobus T, van der Laak JA, Maas MC, Hambrock T, Bruggink CC, Hulsbergen-van de Kaa CA, Scheenen TW, Heerschap A. Contribution of histopathologic tissue composition to quantitative mr spectroscopy and diffusion-weighted imaging of the prostate. Radiology. 2016;278(3):801-11. doi: 10.1148/radiol.2015142889. PMID 26418614.

Robatjazi M, Pashazadeh AM, Karimi H, Assadi M. Mol imaging magn reson spectrosc (MRS). ISMJ. 2015;18(1):210-21.

Carter HB. Diagnosis and staging of prostate cancer. Campbell’s Urol. 1998;3:2519-37.

Ikonen S, Kivisaari L, Tervahartiala P, Vehmas T, Taari K, Rannikko S. Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol. 2001;42(4):348-54. doi: 10.1034/j.1600-0455.2001.420402.x’, PMID 11442457.

Hricak H, White S, Vigneron D, Kurhanewicz J, Kosco A, Levin D, Weiss J, Narayan P, Carroll PR. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology. 1994;193(3):703-9. doi: 10.1148/radiology.193.3.7972810, PMID 7972810.

Jager GJ, Severens JL, Thornbury JR, de la Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used?-A decision-analytic approach. Radiology. 2000;215(2):445-51. doi: 10.1148/radiology.215.2.r00ap09445, PMID 10796923.

Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. RadioGraphics. 2004;24Suppl 1:S167-S80. doi: 10.1148/24si045516, PMID 15486239.

Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11(2):102-25. doi: 10.1593/neo.81328, PMID 19186405.

Zakiana KL, Hatfieldb W, Arasc O, Caod K, Derya Yakare DA, Goldmanf CS Moskowitzg, Amita Shukla-Daveh, Yousef Mazaheri Tehranii, Samson Finej, James Easthamk, Hedvig Hricakl. Prostate MRSI predicts outcome radic prostatectomy patients magnreson imaging author [manuscript]. PMC. 2017.

Zakian KL, Sircar K, Hricak H, Chen HN, Shukla Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234(3):804-14. doi: 10.1148/ radiol. 2343040363, PMID 15734935.



How to Cite




Review Article(s)